Resverlogix Corp
TSX:RVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Resverlogix Corp
Free Cash Flow
Resverlogix Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Resverlogix Corp
TSX:RVX
|
Free Cash Flow
-$4.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Free Cash Flow
-CA$8.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Free Cash Flow
$135.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Free Cash Flow
-$279.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-31%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Free Cash Flow
-CA$29.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-136%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Free Cash Flow
-$100.7m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Resverlogix Corp
Glance View
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.
See Also
What is Resverlogix Corp's Free Cash Flow?
Free Cash Flow
-4.4m
USD
Based on the financial report for Dec 31, 2025, Resverlogix Corp's Free Cash Flow amounts to -4.4m USD.
What is Resverlogix Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-6%
Over the last year, the Free Cash Flow growth was 0%. The average annual Free Cash Flow growth rates for Resverlogix Corp have been -3% over the past three years , -6% over the past five years .
